Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11475203 | 0.88 | PIK3CD (0.41) | PIK3CDEPHX2EPHX1RORCRAB9A | |
| SCHEMBL24272054 | 0.86 | PIK3CD (0.38) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL11471617 | 0.85 | PIK3CD (0.39) | PIK3CDEPHX2EPHX1RORCRAB9A | |
| SCHEMBL27691006 | 0.84 | RAB9A (0.39) | RAB9AHCRTR2 | |
| SCHEMBL23695839 | 0.84 | MEN1 (0.40) | EPHX2RAB9A | |
| SCHEMBL24509165 | 0.83 | EPHX2 (0.43) | PIK3CDEPHX2EPHX1 | |
| SCHEMBL11487660 | 0.80 | MAPT (0.38) | PIK3CDEPHX2EPHX1RAB9AMAPT | |
| SCHEMBL24672696 | 0.80 | PIK3CD (0.41) | PIK3CDEPHX2EPHX1RORCRAB9A | |
| SCHEMBL4572154 | 0.79 | MAPT (0.44) | EPHX2EPHX1CYP1A2TDP1MAPT | |
| SCHEMBL3508110 | 0.79 | KCNK3 (0.40) | PIK3CDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885EPHX2 1890/4885EPHX1 1684/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885EPHX2 1890/4885EPHX1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.